Novogen (NASDAQ:KZIA) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Novogen (NASDAQ:KZIA) from a hold rating to a buy rating in a research note issued to investors on Saturday morning.

KZIA has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Novogen in a report on Wednesday, January 28th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Novogen currently has a consensus rating of “Hold” and an average price target of $19.00.

Novogen Stock Performance

Shares of Novogen stock opened at $8.45 on Friday. Novogen has a 1 year low of $2.86 and a 1 year high of $17.40. The business has a 50 day moving average price of $6.63 and a 200 day moving average price of $7.73.

Novogen (NASDAQ:KZIA) last issued its earnings results on Friday, November 7th. The company reported ($6.14) earnings per share for the quarter. The company had revenue of $0.59 million during the quarter.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.